Fibroblast Insights into the Pathogenesis of Ankylosing Spondylitis

References

• Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–1390. doi:10.1016/S0140-6736(07)60635-7
   PubMed Web of Science ®Google Scholar
• de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016;18(1):196. doi:10.1186/s13075-016-1093-z
   PubMed Web of Science ®Google Scholar
• Navarro-Compán V, Sepriano A, El-Zorkany B, et al. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511–1521. doi:10.1136/annrheumdis-2021-221035
   PubMed Web of Science ®Google Scholar
• Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: an autoimmune or autoinflammatory disease?. Nat Rev Rheumatol. 2021;17(7):387–404. doi:10.1038/s41584-021-00625-y
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther. 2008;10(5):R104. doi:10.1186/ar2496
   PubMed Web of Science ®Google Scholar
• Shao F, Liu Q, Zhu Y, et al. Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis. Nat Commun. 2021;12(1):6540. doi:10.1038/s41467-021-26750-6
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–i44. doi:10.1136/ard.2008.104018
   PubMed Web of Science ®Google Scholar
• Min Wang D, Lin L, Hua Peng J, et al. Pannus inflammation in sacroiliitis following immune pathological injury and radiological structural damage: a study of 193 patients with spondyloarthritis. Arthritis Res Ther. 2018;20(1):120. doi:10.1186/s13075-018-1594-z
   PubMedGoogle Scholar
• François RJ, Gardner DL, Degrave EJ, Bywaters EGL. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis: systematic study of specimens from patients and control subjects. Arthritis Rheum. 2000;43(9):2011–2024. doi:10.1002/1529-0131(200009)43:9<2011::AID-ANR12>3.0.CO;2-Y
   PubMedGoogle Scholar
• Bleil J, Maier R, Hempfing A, et al. Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis. Arthritis Rheumatol. 2014;66(7):1745–1754. doi:10.1002/art.38404
   PubMed Web of Science ®Google Scholar
• Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum. 2008;58(3):649–656. doi:10.1002/art.23260
   PubMedGoogle Scholar
• Bleil J, Maier R, Hempfing A, Sieper J, Appel H, Syrbe U. Granulation tissue eroding the subchondral bone also promotes new bone formation in ankylosing spondylitis. Arthritis Rheumatol. 2016;68(10):2456–2465. doi:10.1002/art.39715
   PubMed Web of Science ®Google Scholar
• Lories RJ, Luyten FP. Activated fibrocytes: circulating cells that populate the arthritic synovium? Rheumatology. 2010;49(4):617–618. doi:10.1093/rheumatology/kep365
   PubMed Web of Science ®Google Scholar
• Lories RJU, Matthys P, de Vlam K, Derese I, Luyten FP. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis. Ann Rheum Dis. 2004;63(5):595–598. doi:10.1136/ard.2003.013599
   PubMed Web of Science ®Google Scholar
• Yang M, Yuan H, Miao M, Xu W. The osteogenic potential of ligament fibroblasts is greater in ankylosing spondylitis patients than in patients with osteoarthritis. Zeitschrift fur Rheumatol. 2015;74(4):340–345. doi:10.1007/s00393-014-1394-z
   PubMed Web of Science ®Google Scholar
• Jiang N, Liu H-X, Liang H-Y, Feng X-H, Liu B-Y, Zhou Y-Y. Osteogenic differentiation characteristics of Hip joint capsule fibroblasts obtained from patients with ankylosing spondylitis. Ann Transl Med. 2021;9(4):331. doi:10.21037/atm-20-7817
   PubMed Web of Science ®Google Scholar
• Buechler MB, Pradhan RN, Krishnamurty AT, et al. Cross-tissue organization of the fibroblast lineage. Nature. 2021;593(7860):575–579. doi:10.1038/s41586-021-03549-5
   PubMed Web of Science ®Google Scholar
• Neumann E, Lefèvre S, Zimmermann B, et al. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med. 2010;16(10):458–468. doi:10.1016/j.molmed.2010.07.004
   PubMed Web of Science ®Google Scholar
• Zhang X-P, Jian-Da M, Ying-Qian M, et al. Addition of fibroblast-stromal cell markers to immune synovium pathotypes better predicts radiographic progression at 1 year in active rheumatoid arthritis. Front Immunol. 2021;12:778480. doi:10.3389/fimmu.2021.778480
   PubMed Web of Science ®Google Scholar
• Qin X, Zhu B, Jiang T, et al. miR-17-5p regulates heterotopic ossification by targeting ANKH in ankylosing spondylitis. Mol Ther Nucleic Acids. 2019;18:696–707. doi:10.1016/j.omtn.2019.10.003
   PubMedGoogle Scholar
• Yeremenko N, Noordenbos T, Cantaert T, et al. Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis. Arthritis Rheum. 2013;65(1):174–185. doi:10.1002/art.37704
   PubMedGoogle Scholar
• Mauro D, Simone D, Bucci L, Ciccia F. Novel immune cell phenotypes in spondyloarthritis pathogenesis. Semi Immunopathol. 2021;43(2):265–277. doi:10.1007/s00281-021-00837-0
   PubMed Web of Science ®Google Scholar
• Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18(7):415–429. doi:10.1038/s41584-022-00793-5
   PubMed Web of Science ®Google Scholar
• Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16(6):316–333. doi:10.1038/s41584-020-0413-5
   PubMed Web of Science ®Google Scholar
• Chu C-Q. Highlights of strategies targeting fibroblasts for novel therapies for rheumatoid arthritis. Front Med. 2022;9:846300. doi:10.3389/fmed.2022.846300
   Web of Science ®Google Scholar
• Teitelbaum SL, Patrick Ross F. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638–649. doi:10.1038/nrg1122
   PubMed Web of Science ®Google Scholar
• Canalis E. Notch signaling in osteoblasts. Sci Signal. 2008;1(17):e17. doi:10.1126/stke.117pe17
   Web of Science ®Google Scholar
• Nakahama K-I. Cellular communications in bone homeostasis and repair. Cell Mol Life Sci. 2010;67(23):4001–4009. doi:10.1007/s00018-010-0479-3
   PubMed Web of Science ®Google Scholar
• Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289(5484):1501–1504. doi:10.1126/science.289.5484.1501
   PubMed Web of Science ®Google Scholar
• Correa‐Gallegos D, Jiang D, Rinkevich Y. Fibroblasts as confederates of the immune system. Immunol Rev. 2021;302(1):147–162. doi:10.1111/imr.12972
   PubMed Web of Science ®Google Scholar
• Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: t cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis. 2000;59(2):135–140. doi:10.1136/ard.59.2.135
   PubMed Web of Science ®Google Scholar
• Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of Hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum. 2006;54(6):1805–1813. doi:10.1002/art.21907
   PubMed Web of Science ®Google Scholar
• Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10(13):4025–4031. doi:10.1002/j.1460-2075.1991.tb04978.x
   PubMed Web of Science ®Google Scholar
• Ward MM, Bruckel J, Colbert R, et al. Summary of the 2005 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol. 2006;33(5):978–982.
   PubMedGoogle Scholar
• Péntek M, Poór G, Wiland P, et al. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econom. 2014;15(Suppl 1):S35–S43. doi:10.1007/s10198-014-0592-6
   PubMed Web of Science ®Google Scholar
• Baji P, Péntek M, Szántó S, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econom. 2014;15(Suppl 1):S45–S52. doi:10.1007/s10198-014-0593-5
   PubMed Web of Science ®Google Scholar
• Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18(4):205–216. doi:10.1038/s41584-022-00761-z
   PubMed Web of Science ®Google Scholar
• Deodhar A, David Y. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheumatism. 2017;47(3):343–350. doi:10.1016/j.semarthrit.2017.04.005
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–1713. doi:10.1016/S0140-6736(13)61134-4
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Song I-H, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, Phase 2/3 trial. Lancet. 2019;394(10214):2108–2117. doi:10.1016/S0140-6736(19)32534-6
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Peihua W, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13(3):R95. doi:10.1186/ar3370
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019;15(12):747–757. doi:10.1038/s41584-019-0294-7
   PubMed Web of Science ®Google Scholar
• Wei K, Nguyen HN, Brenner MB. Fibroblast pathology in inflammatory diseases. J Clin Invest. 2021;131(20). doi:10.1172/JCI149538
   Web of Science ®Google Scholar
• Peng J, Gong Y, Zhang Y, Wang D, Xiao Z. Immunohistological analysis of active sacroiliitis in patients with axial spondyloarthritis. Medicine. 2017;96(16):e6605. doi:10.1097/MD.0000000000006605
   PubMed Web of Science ®Google Scholar
• Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 2006;54(9):2845–2851. doi:10.1002/art.22060
   PubMedGoogle Scholar
• Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis. 2005;64(4):529–536. doi:10.1136/ard.2003.018549
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62(5):1290–1297. doi:10.1002/art.27383
   PubMed Web of Science ®Google Scholar
• Liu L, Yuan Y, Zhang S, Jiake X, Zou J. Osteoimmunological insights into the pathogenesis of ankylosing spondylitis. J Cell Physiol. 2021;236(9):6090–6100. doi:10.1002/jcp.30313
   PubMed Web of Science ®Google Scholar
• Cambré I, Gaublomme D, Burssens A, et al. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nat Commun. 2018;9(1):4613. doi:10.1038/s41467-018-06933-4
   PubMed Web of Science ®Google Scholar
• Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs. 2009;23(2):111–124. doi:10.2165/00063030-200923020-00004
   PubMed Web of Science ®Google Scholar
• Batko B, Maga P, Urbanski K, et al. Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment. Sci Rep. 2018;8(1):13205. doi:10.1038/s41598-018-31550-y
   PubMedGoogle Scholar
• Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest. 2000;80(8):1195–1205. doi:10.1038/labinvest.3780127
   PubMed Web of Science ®Google Scholar
• Liu C-H, Raj S, Chen C-H, et al. HLA-B27-mediated activation of TNAP phosphatase promotes pathogenic syndesmophyte formation in ankylosing spondylitis. J Clin Invest. 2019;129(12):5357–5373. doi:10.1172/JCI125212
   PubMed Web of Science ®Google Scholar
• Saetia K, Cho D, Lee S, Kim DH, Kim SD. Ossification of the posterior longitudinal ligament: a review. Neurosurgical Focus. 2011;30(3):E1. doi:10.3171/2010.11.FOCUS10276
   PubMed Web of Science ®Google Scholar
• Le HV, Wick JB, Van BW, Klineberg EO. Ossification of the posterior longitudinal ligament: pathophysiology, diagnosis, and management. J Am Aca Orthopa Surg. 2022;30(17):820–830. doi:10.5435/JAAOS-D-22-00049
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. Clin Rheumatol. 2000;19(1):51–57. doi:10.1007/s100670050011
   PubMed Web of Science ®Google Scholar
• Laloo F, Herregods N, Jaremko JL, et al. MRI of the axial skeleton in spondyloarthritis: the many faces of new bone formation. Insights Imaging. 2019;10(1):67. doi:10.1186/s13244-019-0752-4
   PubMed Web of Science ®Google Scholar
• Tam L-S, Jieruo G, David Y. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol. 2010;6(7):399–405. doi:10.1038/nrrheum.2010.79
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;14(11):631–640. doi:10.1038/s41584-018-0091-8
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–176. doi:10.1016/S0092-8674(00)81569-X
   PubMed Web of Science ®Google Scholar
• Danks L, Komatsu N, Guerrini MM, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis. 2016;75(6):1187–1195. doi:10.1136/annrheumdis-2014-207137
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Boehm H, Bahrami R, et al. What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. Ann Rheum Dis. 2019;78(9):1220–1225. doi:10.1136/annrheumdis-2018-214983
   PubMed Web of Science ®Google Scholar
• Osta B, Lavocat F, Eljaafari A, Miossec P. Effects of Interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front Immunol. 2014;5:425. doi:10.3389/fimmu.2014.00425
   PubMed Web of Science ®Google Scholar
• Shin HR, Kim BS, Kim HJ, et al. Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice. J Cell Physiol. 2022;237(4):2155–2168.
   PubMed Web of Science ®Google Scholar
• Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008;58(3):718–729. doi:10.1002/art.23290
   PubMedGoogle Scholar
• Bharadwaz A, Jayasuriya AC. Osteogenic differentiation cues of the bone morphogenetic protein-9 (BMP-9) and its recent advances in bone tissue regeneration. Mater Sci Eng C. 2021;120:111748. doi:10.1016/j.msec.2020.111748
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Wichuk S, Chiowchanwisawakit P, Lambert RG, Pedersen SJ. Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis. Arthritis Rheumatol. 2014;66(11):2958–2967. doi:10.1002/art.38792
   PubMed Web of Science ®Google Scholar
• Chiowchanwisawakit P, Lambert RGW, Conner-Spady B, Maksymowych WP. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum. 2011;63(8):2215–2225. doi:10.1002/art.30393
   PubMedGoogle Scholar
• Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73(10):1819–1825. doi:10.1136/annrheumdis-2013-203425
   PubMed Web of Science ®Google Scholar
• Wei-Dong X, Yang X-Y, Da-He L, et al. Up-regulation of fatty acid oxidation in the ligament as a contributing factor of ankylosing spondylitis: a comparative proteomic study. J proteo. 2015;113:57–72. doi:10.1016/j.jprot.2014.09.014
   Google Scholar
• Plikus MV, Guerrero-Juarez CF, Ito M, et al. Regeneration of fat cells from myofibroblasts during wound healing. Science. 2017;355(6326):748–752. doi:10.1126/science.aai8792
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063–3070. doi:10.1002/art.23901
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324–1331. doi:10.1002/art.23471
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with Adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. doi:10.1186/ar2794
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann K-GA, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014;73(6):1107–1113. doi:10.1136/annrheumdis-2012-203075
   PubMed Web of Science ®Google Scholar
• Pakshir P, Noskovicova N, Lodyga M, et al. The myofibroblast at a glance. J Cell Sci. 2020;133(13). doi:10.1242/jcs.227900
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hongfei X, Hu X, Zhang C, Chu T, Zhou Y. Histopathological changes in supraspinous ligaments, ligamentum flava and paraspinal muscle tissues of patients with ankylosing spondylitis. Int J Rheum Dis. 2016;19(4):420–429. doi:10.1111/1756-185X.12305
   PubMed Web of Science ®Google Scholar
• Murshed M. Mechanism of Bone Mineralization. Cold Spring Harb Perspect Med. 2018;8(12):a031229. doi:10.1101/cshperspect.a031229
   PubMed Web of Science ®Google Scholar
• Beyer C, Distler JHW. Changing paradigms in spondylarthritis: the myofibroblast signature. Arthritis Rheum. 2013;65(1):24–27. doi:10.1002/art.37703
   PubMedGoogle Scholar
• Nanthakumar CB, Hatley RJD, Lemma S, Gauldie J, Marshall RP, Macdonald SJF. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov. 2015;14(10):693–720. doi:10.1038/nrd4592
   PubMed Web of Science ®Google Scholar
• Stougaard J, Lomholt S, Ommen P, Kelsen J, Kragstrup TW. The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro. BMC Rheumatol. 2018;2:33.
   PubMedGoogle Scholar
• Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–192. doi:10.1038/nm.3074
   PubMed Web of Science ®Google Scholar
• Tang SL, Huang QH, Wu LG, Liu C, Cai AL. MiR-124 regulates osteoblast differentiation through GSK-3β in ankylosing spondylitis. Eur Rev Med Pharmacol Sci. 2018;22(20):6616–6624. doi:10.26355/eurrev_201810_16136
   PubMed Web of Science ®Google Scholar
• Zou Y-C, Yang X-W, Yuan S-G, Zhang P, Yi-Kai L. Celastrol inhibits prostaglandin E2-induced proliferation and osteogenic differentiation of fibroblasts isolated from ankylosing spondylitis Hip tissues in vitro. Drug Design Dev Ther. 2016;10:933–948. doi:10.2147/DDDT.S97463
   PubMed Web of Science ®Google Scholar
• Du W, Yin L, Tong P. MiR-495 targeting dvl-2 represses the inflammatory response of ankylosing spondylitis. Am J Transl Res. 2019;11(5):2742–2753.
   PubMed Web of Science ®Google Scholar
• Patel MS, Karsenty G. Regulation of bone formation and vision by LRP5. New Eng J Med. 2002;346(20):1572–1574. doi:10.1056/NEJM200205163462011
   PubMed Web of Science ®Google Scholar
• Zou Y-C, Yang X-W, Yuan S-G, Zhang P, Yong-Liang Y, Yi-Kai L. Downregulation of dickkopf-1 enhances the proliferation and osteogenic potential of fibroblasts isolated from ankylosing spondylitis patients via the Wnt/β-catenin signaling pathway in vitro. Connect Tissue Res. 2016;57(3):200–211. doi:10.3109/03008207.2015.1127916
   PubMed Web of Science ®Google Scholar
• Di G, Kong L, Zhao Q, Ding T. MicroRNA-146a knockdown suppresses the progression of ankylosing spondylitis by targeting dickkopf 1. Biomed Pharmacother. 2018;97:1243–1249. doi:10.1016/j.biopha.2017.11.067
   PubMed Web of Science ®Google Scholar
• Resende GG, Machado CRL, Rocha MA, et al. IL-22 increases the production of sFRP3 by FLS in inflammatory joint diseases. Braz J Med Biol. 2020;53(9):e9880. doi:10.1590/1414-431x20209880
   PubMed Web of Science ®Google Scholar
• Xindong H, Dong Y. Ankylosis progressive homolog upregulation inhibits cell viability and mineralization during fibroblast ossification by regulating the Wnt/β‑catenin signaling pathway. Mol Med Rep. 2020;22(6):4551–4560. doi:10.3892/mmr.2020.11576
   PubMed Web of Science ®Google Scholar
• Feng X, Zhu S, Yan Z, Wang C, Tong W, Weidong X. PDGFRB as a potential therapeutic target of ankylosing spondylitis: validation following bioinformatics analysis. Cell Mol Biol. 2020;66(6):127–134. doi:10.14715/cmb/2020.66.6.23
   PubMed Web of Science ®Google Scholar
• Chongru H, Dahe L, Gao J, Jia L, Liu Z, Weidong X. Inhibition of CXCR4 inhibits the proliferation and osteogenic potential of fibroblasts from ankylosing spondylitis via the Wnt/β‑catenin pathway. Mol Med Rep. 2019;19(4):3237–3246. doi:10.3892/mmr.2019.9980
   PubMed Web of Science ®Google Scholar
• Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science. 2002;296(5573):1646–1647. doi:10.1126/science.1071809
   PubMed Web of Science ®Google Scholar
• Lories RJU, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115(6):1571–1579. doi:10.1172/JCI23738
   PubMed Web of Science ®Google Scholar
• Thatcher JD. The TGF-beta signal transduction pathway. Sci Signal. 2010;3(119):tr4. doi:10.1126/scisignal.3119tr4
   PubMed Web of Science ®Google Scholar
• Nishimura R, Hata K, Harris SE, Ikeda F, Yoneda T. Core-binding factor alpha 1 (Cbfa1) induces osteoblastic differentiation of C2C12 cells without interactions with Smad1 and Smad5. Bone. 2002;31(2):303–312. doi:10.1016/S8756-3282(02)00826-8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen W-G, Yang S-Z, et al. Up-regulation of TβRIII facilitates the osteogenesis of supraspinous ligament-derived fibroblasts from patients with ankylosing spondylitis. J Cell Mol Med. 2021;25(3):1613–1623. doi:10.1111/jcmm.16262
   PubMed Web of Science ®Google Scholar
• Jia C, Liu H, Min L, Zhikui W, Feng X. Effects of icariin on cytokine-induced ankylosing spondylitis with fibroblastic osteogenesis and its molecular mechanism. Int J Clin Exp Pathol. 2014;7(12):9104–9109.
   PubMed Web of Science ®Google Scholar
• Zhou Y-Y, Liu H-X, Jiang N, et al. Elemene, the essential oil of Curcuma wenyujin, inhibits osteogenic differentiation in ankylosing spondylitis. Joint Bone Spine. 2015;82(2):100–103. doi:10.1016/j.jbspin.2014.05.004
   PubMed Web of Science ®Google Scholar
• Zhou Y-Y, Huang R-Y, Lin J-H, Xu -Y-Y, He X-H, He Y-T. Bushen-Qiangdu-Zhilv decoction inhibits osteogenic differentiation of rat fibroblasts by regulating connexin 43. Exp Ther Med. 2016;12(1):347–353. doi:10.3892/etm.2016.3292
   PubMed Web of Science ®Google Scholar
• Liu H-X, Jiang N, Liang H-Y, et al. Bushen Qiangji Granule medicated serum inhibits osteogenic differentiation of fibroblasts in ankylosing spondylitis by inhibiting the BMP/Smads signal pathway in vitro. Chin J Integr Med. 2016;22(11):817–822. doi:10.1007/s11655-016-2268-9
   PubMed Web of Science ®Google Scholar
• Wang G, Cai J, Zhang J, Cuiyun L. Mechanism of triptolide in treating ankylosing spondylitis through the anti‑ossification effect of the BMP/Smad signaling pathway. Mol Med Rep. 2018;17(2):2731–2737. doi:10.3892/mmr.2017.8117
   PubMed Web of Science ®Google Scholar
• Yuan B, Zhiming W. MMP-2 silencing reduces the osteogenic transformation of fibroblasts by inhibiting the activation of the BMP/Smad pathway in ankylosing spondylitis. Oncol Letters. 2018;15(3):3281–3286. doi:10.3892/ol.2017.7714
   PubMed Web of Science ®Google Scholar
• Ding L, Yin Y, Hou Y, et al. microRNA-214-3p suppresses ankylosing spondylitis fibroblast osteogenesis BMP-TGF axis and BMP2. Front Endocrinol. 2020;11:609753. doi:10.3389/fendo.2020.609753
   PubMed Web of Science ®Google Scholar
• Liu KG, He QH, Tan JW, Liao GJ. Expression of TNF-α, VEGF, and MMP-3 mRNAs in synovial tissues and their roles in fibroblast-mediated osteogenesis in ankylosing spondylitis. Gene Mole Res. 2015;14(2):6852–6858. doi:10.4238/2015.June.18.28
   PubMed Web of Science ®Google Scholar
• Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem. 2008;283(12):7628–7637. doi:10.1074/jbc.M704883200
   PubMed Web of Science ®Google Scholar
• Hashida Y, Nakahama K-I, Shimizu K, Akiyama M, Harada K, Morita I. Communication-dependent mineralization of osteoblasts via gap junctions. Bone. 2014;61:19–26. doi:10.1016/j.bone.2013.12.031
   PubMed Web of Science ®Google Scholar
• Yang H-S, Xu-hua L, Chen D-Y, et al. Upregulated expression of connexin43 in spinal ligament fibroblasts derived from patients presenting ossification of the posterior longitudinal ligament. Spine. 2011;36(26):2267–2274. doi:10.1097/BRS.0b013e31820ccfc6
   PubMed Web of Science ®Google Scholar
• Qin X, Jiang T, Liu S, et al. Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis: an in vitro study. J Cell Biochem. 2018;119(1):1074–1082. doi:10.1002/jcb.26275
   PubMed Web of Science ®Google Scholar
• Chen S, van Tok MN, Knaup VL, et al. mTOR blockade by rapamycin in spondyloarthritis: impact on inflammation and new bone formation and. Front Immunol. 2019;10:2344. doi:10.3389/fimmu.2019.02344
   PubMed Web of Science ®Google Scholar
• Li DH, He CR, Liu F-P, et al. Annexin A2, up-regulated by IL-6, promotes the ossification of ligament fibroblasts from ankylosing spondylitis patients. Biomed Pharmacother. 2016;84:674–679. doi:10.1016/j.biopha.2016.09.091
   PubMed Web of Science ®Google Scholar
• Assadiasl S, Rajabinejad M, Soleimanifar N, et al. MicroRNAs-mediated regulation pathways in rheumatic diseases. Inflammopharmacology. 2023;31(1):129–144. doi:10.1007/s10787-022-01097-6
   PubMed Web of Science ®Google Scholar
• Najm A, Blanchard F, Le Goff B. Micro-RNAs in inflammatory arthritis: from physiopathology to diagnosis, prognosis and therapeutic opportunities. Biochem Pharmacol. 2019;165:134–144. doi:10.1016/j.bcp.2019.02.031
   PubMed Web of Science ®Google Scholar
• Fangcang Y, Cui Y, Zhou X, Zhang X, Han J. Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells. Biosci Trends. 2011;5(2):46–51. doi:10.5582/bst.2011.v5.2.46
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang C, Jia Z. Differentially expressed mRNAs, lncRNAs, and miRNAs with associated co-expression and ceRNA networks in ankylosing spondylitis. Oncotarget. 2017;8(69):113543–113557. doi:10.18632/oncotarget.22708
   PubMedGoogle Scholar
• Zou Y-C, Yan L-M, Gao Y-P, et al. miR-21 may act as a potential mediator between inflammation and abnormal bone formation in ankylosing spondylitis based on TNF-α concentration-dependent manner through the JAK2/STAT3 pathway. Dose-Response. 2020;18(1):1559325819901239. doi:10.1177/1559325819901239
   Web of Science ®Google Scholar
• Guangxue G, Huo Y, Gang X, et al. MicroRNA-204-GSDMD interaction regulates pyroptosis of fibroblast-like synoviocytes in ankylosing spondylitis. Int Immunopharmacol. 2021;91:107227. doi:10.1016/j.intimp.2020.107227
   PubMed Web of Science ®Google Scholar
• Xia L, Zhou W, Zhen L, Guan F. Hsa_circ_0056558 regulates cyclin-dependent kinase 6 by sponging microRNA-1290 to suppress the proliferation and differentiation in ankylosing spondylitis. Autoimmunity. 2021;54(2):114–128. doi:10.1080/08916934.2021.1894417
   PubMed Web of Science ®Google Scholar
• Yu C, Zhan X, Liang T, et al. Mechanism of hip arthropathy in ankylosing spondylitis: abnormal myeloperoxidase and phagosome. Front Immunol. 2021;12:572592. doi:10.3389/fimmu.2021.572592
   PubMed Web of Science ®Google Scholar
• van Tok MN, van Duivenvoorde LM, Kramer I, et al. Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis. Arthritis Rheumatol. 2019;71(4):612–625. doi:10.1002/art.40770
   PubMed Web of Science ®Google Scholar
• Gracey E, Burssens A, Cambré I, et al. Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. Nat Rev Rheumatol. 2020;16(4):193–207. doi:10.1038/s41584-019-0364-x
   PubMed Web of Science ®Google Scholar
• Zihao L, Chen S, Cui H, et al. Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis. Ann Rheum Dis. 2021;80(7):891–902. doi:10.1136/annrheumdis-2021-220002
   PubMed Web of Science ®Google Scholar
• Van Mechelen M, Lories R. Tenascin-C, a novel target to inhibit new bone formation in axial spondyloarthritis, linked with inflammation, mechanical strain and tissue damage. Ann Rheum Dis. 2021;80(7):823–824. doi:10.1136/annrheumdis-2021-220443
   PubMed Web of Science ®Google Scholar